Alzheimer’s Disease (AD) – Current Treatment Insights Report – 2025

Alzheimer’s Disease (AD) Current Treatment Insights

Thelansis’s “Alzheimer’s Disease (AD) Current Treatment Insights Report – 2025″ describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.

Alzheimer’s Disease (AD) Overview

Alzheimer’s disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of neurons, and fragments of other nerve cells. Neurofibrillary tangles (NETs), knotted bundles of fibers containing clusters of a protein known as tau, are situated within neurons. The deterioration of connections between neurons leads to memory and learning deficits. Alzheimer’s disease exhibits distinctive brain alterations (pathology) distinct from those of other causes of dementia, such as Lewy body disease or Cerebrovascular disease. When these coexisting pathologies are identified during a person’s lifetime, it is called mixed dementia.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician specialty(ies) involved in the diagnosis and treatment of patients:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Patient characteristics/patient segments
• Patient diagnosis criteria
• Patient shares for current therapies
• Line of therapy analysis
• Treatment sequencing
• Patient journey
• Compliance and persistency analysis
• Polypharmacy
• Factors impacting physician choice of treatments
• Drivers and barriers to prescribing key brands/treatments
• Physician-perceived advantages and disadvantages of current therapies
• Evolving treatment landscape
• KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)